Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric E. Poma
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Beta
- 1.33
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -36.31
Financials
Revenue
$0.00-100.0%Net Income
$-4.16MEBITDA
$-3.68MFree Cash Flow
$-4.35MEPS (diluted)
$-2.94Shares Outstanding (diluted)
1.42M+9394.4%Operating Expenses
$4.15MCash & Debt
$4.07MReturn of Capital
$309.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-19.91M | $-95.20 |
| 2024 | $0.00 | $-22.14M | $-571.20 |
| 2023 | $0.00 | $-29.22M | $-3321.76 |
| 2022 | $45.0K | $-25.43M | $-5740.80 |
| 2021 | $449.0K | $-10.93M | $226.56 |
| 2020 | $0.00 | $-7.94M | $-42.24 |
Valuation
CLDIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·6h ago·Negative
…ew CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026 SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, announced that it will be presenting two posters at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026. The presentations will showcase the Company's …
View source ↗ - Newsglobenewswire.com·23d ago·Negative
…YSE American Notification Letter Regarding Stockholders' Equity Deficiency SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the Company received a notice (the “Notice”) from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's contin…
View source ↗ - Newsglobenewswire.com·66d ago·Neutral
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027
View source ↗
Earnings
Tue, Nov 17(in 4 weeks)
Typical surprise -3.6% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Mar 27$-9.12 vs $-24.96beat
- Tue, Nov 11$-35.36 vs $-26.88miss
- Tue, Aug 12$-31.84 vs $-30.72miss
- Tue, May 13$-34.56 vs $-28.80miss
- Fri, Apr 4$-51.84 vs $-71.04beat
Estimates and results for CLDI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLDI officers and directors.
- Bought
- $910k
- Sold
- $17k
8 trades
2 trades
- Camaisa Allansold
- Schoeneck James Abought
- Schoeneck James Abought
- Poma Eric Ebought
- Poma Eric Ebought
- Leftwich Scottbought
- Leftwich Scottbought
- Jackson Andrew C.bought
49 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CLDI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.